In 2017, global revenue of Hyperimmune Globulins is nearly 1150 million USD; the actual production is about 40 million units.
Thursday, 20 Sep, 2018

Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.

 

In the last several years, global market of Hyperimmune Globulins developed rapidly, with an average growth rate of 6%. In 2017, global revenue of Hyperimmune Globulins is nearly 1150 million USD; the actual production is about 40 million units.

 

The classification includes the Hepatitis B Immunoglobulins, Rabies Immunoglobulins, Tetanus Immunoglobulins and others, and the proportion of Rabies Immunoglobulins in 2017 is about 44.2%, with the largest market share.

 

Hyperimmune Globulins is widely used in Government Institutions, Private Sector and Other. The most proportion of Hyperimmune Globulins is sold in Government Institutions, and the proportion in 2017 is about 62.7%.

 

North America is the largest supply place, with a production market share nearly 28.8% in 2017. Following North America, China is the second largest supply place with the production market share of 28.5%, and the market share of Europe is about 26.1%.

 

China is the largest consumption place, with a consumption market share nearly 28.5% in 2017. China is an important market of Blood Product in Asia, Following China, North America is the second largest consumption place with the consumption market share of 26.6%, and the market share of Europe is about 24.2%.